Jupiter Wellness, Inc. JUPW
We take great care to ensure that the data presented and summarized in this overview for Jupiter Wellness, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding JUPW
View all-
Glenview Trust CO Louisville, KY1.99MShares$5.81 Million0.11% of portfolio
-
Black Rock Inc. New York, NY678KShares$1.98 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA532KShares$1.55 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA459KShares$1.34 Million0.0% of portfolio
-
Steward Partners Investment Advisory, LLC210KShares$614,0580.01% of portfolio
-
Xtx Topco LTD London, X0162KShares$472,8030.03% of portfolio
-
State Street Corp Boston, MA146KShares$426,6120.0% of portfolio
-
Franklin Resources Inc San Mateo, CA90.1KShares$263,0620.0% of portfolio
-
Northern Trust Corp Chicago, IL73.9KShares$215,7290.0% of portfolio
-
Morgan Stanley New York, NY69.4KShares$202,5890.0% of portfolio
Latest Institutional Activity in JUPW
Top Purchases
Top Sells
About JUPW
Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CBD-infused sunscreen under the CaniSun brand; CBD-infused skin care lotion under the CaniSkin brand; and products for the dermatological treatments of pain and inflammation under the CaniDermRX brand. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.
Insider Transactions at JUPW
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2024
|
Christopher Melton Director |
SELL
Open market or private sale
|
Direct |
3,470
-5.26%
|
$0
$0.86 P/Share
|
|
Sep 05
2024
|
Jordan Schur President |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|
|
Sep 05
2024
|
Jordan Schur President |
BUY
Grant, award, or other acquisition
|
Indirect |
1,676,944
+50.0%
|
-
|
|
Sep 01
2024
|
Christopher Melton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
66,000
+50.0%
|
$1,089,000,000
$16500.0 P/Share
|
|
Jul 08
2024
|
Jordan Schur President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
250,000
-100.0%
|
-
|
|
Jun 28
2024
|
Jordan Schur President |
BUY
Grant, award, or other acquisition
|
Indirect |
943,396
+17.53%
|
$943,396
$1.06 P/Share
|
|
Jun 14
2024
|
Jordan Schur President |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
$250,000
$1.39 P/Share
|
|
Dec 28
2023
|
John Gulyas Director |
BUY
Open market or private purchase
|
Direct |
5,000
+0.15%
|
$15,000
$3.88 P/Share
|
|
Aug 31
2023
|
John Gulyas Director |
BUY
Open market or private purchase
|
Indirect |
1,666,666
+49.73%
|
-
|
|
Aug 07
2023
|
John Gulyas Director |
BUY
Open market or private purchase
|
Direct |
18,500
+11.74%
|
-
|
|
Oct 25
2022
|
Skender Fani Director |
BUY
Open market or private purchase
|
Direct |
128,120
+34.43%
|
$0
$0.9 P/Share
|
|
Oct 24
2022
|
Skender Fani Director |
BUY
Open market or private purchase
|
Direct |
101
+0.17%
|
$0
$0.83 P/Share
|
|
Oct 20
2022
|
Skender Fani Director |
BUY
Open market or private purchase
|
Direct |
57,839
+50.0%
|
$0
$0.82 P/Share
|
|
Jul 26
2022
|
Brian John Former CEO, Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,664
-0.67%
|
-
|
|
Jul 26
2022
|
Glynn Wilson Former CSO, Chairman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,248
-1.47%
|
-
|
|
Jul 26
2022
|
Richard A Miller CCO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,416
-0.93%
|
-
|
|
Jul 25
2022
|
Douglas O Mckinnon CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,248
-5.91%
|
-
|
|
Nov 10
2021
|
Douglas O Mckinnon CFO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+30.56%
|
-
|
|
Nov 10
2021
|
Glynn Wilson Former CSO, Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+17.3%
|
-
|
|
Oct 06
2021
|
Brian John Former CEO, Director |
BUY
Open market or private purchase
|
Direct |
50,000
+1.77%
|
$50,000
$1.42 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 66K shares |
|---|---|
| Grant, award, or other acquisition | 1.93M shares |
| Open market or private sale | 3.47K shares |
|---|